N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Status:
Not yet recruiting
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 2 open-label study to evaluate the safety and efficacy of N-803 and PD-L1
t-haNK when combined with Bevacizumab in subjects with recurrent or progressive GBM.
Participants will receive N-803 subcutaneously (SC), PD-L1 t-haNK intravenously (IV), and
Bevacizumab IV combination therapy.
Treatment for all enrolled participants will consist of repeated cycles of 28 days for a
maximum treatment period of 76 weeks (19 cycles). Treatment will be administered on days 1
and day 15 of each cycle. Treatment will be discontinued if the participant reports
unacceptable toxicity (not corrected with dose reduction), withdraws consent, if the
Investigator feels it is no longer in the participant's best interest to continue treatment,
or the participant has confirmed progressive disease by iRANO, unless the participant is
potentially deriving benefit per Investigator's assessment. Participants will be followed for
collection of survival status every 12 weeks (± 2 weeks) for the first 2 years, then yearly
thereafter.